2. Search Result
Search Result
Results for "

psoriatic model

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10587
    Icotrokinra

    JNJ-77242113; JNJ-2113; PN-235

    		 Interleukin Related STAT IFNAR Inflammation/Immunology
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra
  • HY-153780
    Navepdekinra

    DC-806; LY4100504; S-011806

    		 Interleukin Related Inflammation/Immunology
    Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis .
    Navepdekinra
  • HY-P99940
    Remtolumab

    ABT-122

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Remtolumab is a bispecific variable domain immunoglobulin molecule with human affinities for TNFα and IL-17 in the low pM range of Kd. Remtolumab can be used in research related to rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis .
    Remtolumab
  • HY-169853
    M351-0056

    		VISTA Inflammation/Immunology
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models .
    M351-0056
  • HY-P10587A
    Icotrokinra acetate

    JNJ-77242113 acetate; JNJ-2113 acetate; PN-235 acetate

    		 Interleukin Related STAT IFNAR Inflammation/Immunology
    Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra acetate
  • HY-168212
    PDE4-IN-22

    		Phosphodiesterase (PDE) TNF Receptor Interleukin Related Inflammation/Immunology
    PDE4-IN-22 (Compound 2e) is a PDE4 inhibitor with an IC50 value of 2.4 nM. PDE4-IN-22 exhibits anti-inflammatory activity and demonstrates significant anti-psoriatic effects in an Imiquimod (HY-B0180)-induced psoriasis mouse model .
    PDE4-IN-22
  • HY-173290
    PDE4D inhibitor 1

    		Phosphodiesterase (PDE) Interleukin Related CXCR TNF Receptor Inflammation/Immunology
    PDE4-IN-1 is a PDE4 inhibitor with high potency (IC50 : 8.6 nM) and selectivity over other PDE subtypes. PDE4-IN-1 inhibits the release of inflammatory cytokines and chemokines. PDE4-IN-1 greatly restores impaired cAMP-CREB signaling pathway. PDE4-IN-1 inhibits proliferation and promotes differentiation to reverse the formation of psoriasis .
    PDE4D inhibitor 1
  • HY-P10587B
    Icotrokinra (hydrochloride)

    JNJ-77242113 (hydrochloride); JNJ-2113 (hydrochloride); PN-235 (hydrochloride)

    		 Interleukin Related STAT IFNAR Inflammation/Immunology
    Icotrokinra (JNJ-77242113) hydrochloride is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra hydrochloride inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra hydrochloride exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra hydrochloride can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra (hydrochloride)
  • HY-183326
    Isosorbide di-(methyl fumarate)

    IDMF

    		 Keap1-Nrf2 Inflammation/Immunology
    Isosorbide di-(methyl fumarate) (IDMF), topical DMF (HY-17363) derivative, is an NRF2/ARE pathway activator. Isosorbide di-(methyl fumarate) downregulates ANCR targets, modulates epithelial differentiation, represses proinflammatory cytokine genes, IL-17A- and TNF-induced keratinocyte genes, psoriatic skin lesion-specific genes, and immune response genes. Isosorbide di-(methyl fumarate) stimulates oxidative stress response gene transcription, reduces erythema and scaling in Imiquimod (HY-B0180)-induced psoriasiform lesions. Isosorbide di-(methyl fumarate) exhibits no genotoxicity or radiation sensitivity in skin fibroblasts, is nonirritating and nonsensitizing in rodent models. Isosorbide di-(methyl fumarate) can be used for the research of psoriasis vulgaris .
    Isosorbide di-(methyl fumarate)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: